---

PATENT LAW – COMPREHENSIVE ANALYTICAL ANSWER

Question 1 + Question 2 (Combined Detailed Academic Analysis)

---

QUESTION 1 (ORIGINAL PROBLEM)

A pharmaceutical company files a patent application in India for a pediatric formulation of the anti-tuberculosis drug bedaquiline, claiming a tablet that disintegrates more quickly in water with improved sweetness and appearance. The formulation uses known substances and known techniques to make the tablet and does not show a significant enhancement in therapeutic efficacy over the known adult formulation. Considering the requirements of the Patents Act, 1970, should the patent be granted?

---

PART I

PATENTABILITY OF PEDIATRIC FORMULATION OF BEDAQUILINE UNDER THE PATENTS ACT, 1970

---

I. Introduction: Pharmaceutical Patent Regime in India

India’s patent regime represents a careful balance between:

• Protection of innovation
• Public health considerations
• Prevention of monopolistic abuse

The Indian Patents Act, 1970 originally excluded product patents for pharmaceuticals. However, after India became a member of the World Trade Organization, amendments were made in 1999, 2002 and 2005 to comply with TRIPS.

Despite this compliance, India inserted strict safeguards such as Section 3(d) to prevent evergreening.

The present problem must be analyzed within this framework.

---

II. Essential Requirements for Patentability

Under Section 2(1)(j) of the Patents Act, an invention must:

1. Be new (novelty)
2. Involve an inventive step
3. Be capable of industrial application

Additionally, it must not fall within Section 3 (non-patentable inventions).

---

III. Step-by-Step Legal Analysis of the Problem

---

1. Novelty (Section 2(1)(j))

Novelty requires that the invention must not be anticipated by prior publication or prior use.

In this case:

• Bedaquiline is already known.
• Adult formulation already exists.
• Pediatric adaptation uses known techniques.

Therefore:

The substance is not new. Only the dosage form is altered.

This raises a Section 3(d) issue.

---

2. Inventive Step (Section 2(1)(ja))

Inventive step requires:

• Technical advance OR
• Economic significance
  AND
• Non-obviousness to a person skilled in the art.

The pediatric formulation includes:

• Faster disintegration
• Improved sweetness
• Better appearance

These are routine pharmaceutical adjustments.

A person skilled in the art of formulation science would consider:

• Adding sweeteners for children
• Using standard disintegrants
• Modifying coating for palatability

Therefore, this modification appears obvious.

---

IV. Section 3(d): The Most Crucial Provision

Section 3(d) states:

A new form of a known substance which does not result in enhancement of known efficacy is not an invention.

Explanation to Section 3(d) includes:

• Salts
• Esters
• Polymorphs
• Isomers
• Derivatives
• New dosage forms

All treated as same substance unless enhanced efficacy is proven.

---

V. Meaning of “Efficacy” – Judicial Interpretation

The most authoritative judgment:

Novartis AG v. Union of India (2013) 6 SCC 1

This case is the cornerstone of pharmaceutical patent law in India.

---

Facts of the Case:

• Novartis sought patent for beta crystalline form of Imatinib Mesylate.
• Claimed better bioavailability.

---

Supreme Court Held:

1. “Efficacy” means therapeutic efficacy.
2. Improved bioavailability is insufficient unless it translates into therapeutic advantage.
3. Section 3(d) is constitutional.
4. The provision prevents evergreening.

The Court stated:

Not all advantageous properties amount to enhanced therapeutic efficacy.

---

VI. Application of Novartis Principle to Present Case

In the pediatric formulation:

Improvements claimed:

• Faster dissolution
• Better taste
• Improved appearance

However:

• No enhanced therapeutic effect.

Under Novartis:

These improvements do not qualify as enhanced therapeutic efficacy.

Thus, Section 3(d) bars patentability.

---

VII. Evergreening and Public Policy

Evergreening refers to:

• Minor modifications
• Extending patent life
• Blocking generic competition

The Indian legislature deliberately introduced Section 3(d) to prevent:

• Abuse of patent monopoly
• Artificial extension of pharmaceutical patents

---

VIII. Public Health Context – Tuberculosis in India

India has a high TB burden.

Granting patents on minor formulation changes may:

• Increase medicine prices
• Affect government TB control programs
• Restrict generic production

Public health considerations are constitutionally relevant under Article 21 (Right to Life).

---

IX. Additional Case Law Strengthening Public Health Approach

Bayer Corporation v. Union of India (2014)

• First compulsory license case.
• Drug Nexavar priced excessively.
• Compulsory license granted.

Principle: Patent rights are not absolute.

---

F. Hoffmann-La Roche Ltd. v. Cipla Ltd. (Delhi High Court, 2008)

Court emphasized:

• Balance between patent rights and public interest.

---

X. Final Conclusion – Question 1

Applying:

• Section 2(1)(j)
• Section 2(1)(ja)
• Section 3(d)
• Novartis judgment

The pediatric formulation:

• Is a new dosage form of known substance.
• Uses known techniques.
• Lacks enhanced therapeutic efficacy.
• Is obvious to a skilled person.

Therefore:

The patent should NOT be granted.

It falls squarely under Section 3(d) prohibition.

---

PART II

QUESTION 2 (ORIGINAL QUESTION)

To what extent has the TRIPS Agreement contributed to the protection and enforcement of patent rights, particularly in developing countries, and what implications does this have with regard to access to essential medicines and technology transfer?

---

I. Introduction to TRIPS

The TRIPS Agreement is one of the most powerful international intellectual property treaties.

It is administered by the:

World Trade Organization

Came into force: 1995.

It sets:

• Minimum standards of IP protection.
• Binding dispute resolution mechanism.

---

II. Core Provisions Relating to Patents

Article 27 – Patentable Subject Matter

• Patents must be available for inventions in all fields of technology.
• No discrimination between imported and locally produced products.

This provision forced developing countries to introduce product patents.

---

Article 33 – Patent Term

• Minimum 20-year patent protection.

---

Article 28 – Exclusive Rights

Patent owner has right to:

• Make
• Use
• Sell
• Import

---

Article 41 – Enforcement

Requires effective enforcement procedures.

---

III. Impact on Developing Countries

Before TRIPS:

India allowed only process patents in pharmaceuticals.

After TRIPS:

India introduced product patents (2005 Amendment).

Effect:

• Strengthened monopoly rights.
• Reduced generic flexibility.

---

IV. Access to Essential Medicines

Problem:

Patent protection increases drug prices.

During HIV/AIDS crisis:

• Patented antiretroviral drugs were unaffordable in Africa.

This led to global controversy.

---

V. Doha Declaration (2001)

To correct imbalance, WTO adopted:

Doha Declaration on the TRIPS Agreement and Public Health

It clarified:

• TRIPS should not prevent public health protection.
• Countries may issue compulsory licenses.
• Members can define national emergencies.

This was a major victory for developing countries.

---

VI. Compulsory Licensing – Practical Example

India used TRIPS flexibility in:

Bayer case (Nexavar)

Drug price reduced from ₹2.8 lakh/month to ₹8,800/month.

This demonstrated:

TRIPS allows flexibility, but countries must actively use it.

---

VII. Technology Transfer under TRIPS

Article 66.2:

Developed countries must provide incentives for technology transfer to least-developed countries.

However:

• Limited practical impact.
• Technology sharing remains restricted.
• Strong patent regime sometimes discourages local innovation.

---

VIII. Critical Evaluation

TRIPS Contribution to Patent Protection:

Very High:

• Global harmonization
• Strong enforcement
• WTO dispute mechanism

Contribution to Access to Medicines:

Mixed:

• Initially restrictive
• Balanced via Doha Declaration

Contribution to Technology Transfer:

Limited:

• Mostly theoretical obligation
• Weak implementation

---

OVERALL CONCLUSION (COMBINED)

1. The pediatric formulation of Bedaquiline fails Section 3(d) and should not be granted patent.
2. TRIPS significantly strengthened patent protection globally.
3. However, its impact on developing countries is complex.
4. Access to medicines requires use of TRIPS flexibilities.
5. Technology transfer remains insufficient in practice.